This is an old revision of the document!
McGill Interdisciplinary Initiative in Infection and Immunity
The McGill Interdisciplinary Initiative in Infection and Immunity (MI4) is a Canadian research organization in Montreal, Quebec. It is based out of McGill University.
History
COVID-19
MI4 provided research funding related to COVID-19 through their “MI4 Emergency COVID-19 Research Funding” program.1) In particular, MI4 participated as a funding partner of the Canadian arm of the first randomized control trial (RCT) testing hydroxychloroquine for the post-exposure prevention of COVID-19, led by principal investigator David Boulware, which began on March 17, 2020.2)
Organization
Partners
MI4's partners within McGill include:3)
- Advanced BioImaging Facility (ABIF)
Funding
MI4 received funding for their “MI4 Emergency COVID-19 Research Funding” program through the McGill University Health Centre Foundation COVID-19 Emergency Fund from:4)
Activities
| MI4 Emergency COVID-19 Research Funding5) | ||
|---|---|---|
| MI4 ECRF Round 2 | ||
| Lead investigators | Project title | Notes |
| Nicole Basta | Real-Time Tracking of COVID-19 Vaccine Development | “Interactive online COVID-19 vaccine tracker to provide the public with real-time updates about progress towards developing a vaccine. This timely, critical resource will improve understanding of vaccine testing and manage expectations about when a vaccine may be available. It will also provide educational materials about the process of developing new vaccines and making them available to communities around the world. The goal of the project is to increase knowledge about and improve trust in vaccines.” |
| Inés Colmegna, Amal Bessissow, David Meger | Use of Technology to Improve Effects of Social Isolation on Hospitalized COVID-19 Patients (TIES-COVID) | “…studying whether video calls from isolated patients to their loved ones can reduce negative emotions and whether this strategy can be used post-COVID-19 to combat loneliness and improve mental health in older adults.” |
External links
1)
, 4)
, 5)
Results of MI4 Emergency COVID-19 Research Funding. MI4. Retrieved May 16, 2023, from https://web.archive.org/web/20230516234033/https://www.mcgill.ca/mi4/mi4-supported-research/emergency-covid-19-research-funding
2)
Lofgren, S. M., Nicol, M. R., Bangdiwala, A. S., Pastick, K. A., Okafor, E. C., Skipper, C. P., Pullen, M. F., Engen, N., Abassi, M., Williams, D. A., Nascene, A. A., Axelrod, M. L., Lother, S. A., MacKenzie, L. J., Drobot, G., Marten, N., Cheng, M. P., Zarychanshi, R., Schwartz, I. S., & Silverman, M. J. (2020). Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19. medRxiv. https://doi.org/10.1101/2020.07.16.20155531
3)
McGill Partners. MI4. Retrieved May 16, 2023, from https://web.archive.org/web/20230516232825/https://www.mcgill.ca/mi4/our-people/mcgill-partners